Glybera (alipogene tipovarvec) is the first human gene therapy which received market approval. According to the distributor Glybera should be given only once in a lifetime.

The LPL expression is driven by the CMV promotor. Can anybody comment on the long term stability of CMV driven expression in human cells? From my own experiments with stable HepG2 and HEK293 cell lines I know that after several cell passages the expression is going down, gene silencing/deletions or whatsoever.

More Michael Marcus Hoffmann's questions See All
Similar questions and discussions